1. Therapeutic plasma exchange plus corticosteroid for the treatment of the thrombotic thrombocytopenic purpura: A single institutional experience in the southern Marmara region of Turkey
- Author
-
Vildan Ozkocaman, Tulay Ozcelik, Ahmet Tunali, Fahir Özkalemkaş, Atilla Ozkan, Rıdvan Ali, Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı., Özkalemkaş, Fahir, Ali, Rıdvan, Özkocaman, Vildan, Özçelik, Tülay, Özkan, Hasan Atilla, Tunalı, Ahmet, AAG-8495-2021, and AAH-1854-2021
- Subjects
Male ,Pediatrics ,Survival rate ,Scoring system ,Turkey ,Salvage therapy ,Turkey (republic) ,Thrombotic thrombocytopenic purpura ,Hemolytic uremic syndrome ,Corticosteroid ,Treatment outcome ,Disease course ,Middle aged ,Cyclosporin ,Mortality rate ,Incidence (epidemiology) ,Hematology ,Plasmapheresis ,Repeated drug dose ,Management ,Retrospective study ,Vincristine ,Creatinine ,Female ,medicine.drug ,Human ,Adult ,Thrombotic Thrombocytopenic Purpura ,Thrombotic Microangiopathies ,Von Willebrand Factor Cleaving Proteinase ,medicine.medical_specialty ,Purpura, thrombotic thrombocytopenic ,TTP ,Adolescent ,Disease-free survival ,Clinical article ,Methylprednisolone ,Article ,Combination chemotherapy ,Drug dose titration ,Therapeutic plasma exchange ,Kidney function ,Median follow-up ,medicine ,Thrombocyte count ,Immunoglobulin ,Corticosteroids ,Humans ,Plasma exchange ,Creatinine blood level ,Hemoglobin ,Disease severity ,Cyclophosphamide ,business.industry ,Hemoglobin determination ,Adrenal cortex hormones ,Retrospective cohort study ,Follow up ,medicine.disease ,Corticosteroid therapy ,Surgery ,Retrospective studies ,Remission induction ,business - Abstract
Thrombotic thrombocytopenic purpura (TTP) is a classic, but not a common disorder of hematology. Plasma exchange (PE) was shown to nearly reverse its 90% mortality rate. However, there are still some fatal outcomes in this dramatic disease. We present our experience of plasma exchange plus corticosteroids for the treatment of TTP in our hospital. Patients with TTP diagnosed between January 1996 and January 2005 were identified by a retrospective review of records of the Uludag University Hospital, Bursa (the largest referral center for adults with this disorder in this region with an estimated 2.2 million residents), which performs all therapeutic PE in the southern Marmara region in Turkey. A total of 11 (6 male, 5 female) patients were treated for TTP during this period. The median age was 39 years (range 18-49). One plasma volume exchange daily plus steroid was the principle treatment in all patients. A total of 295 PE sessions were performed. We have obtained six complete responses (CR) and three partial responses (PR) with daily PE and steroid (response rate 9/11). One of our primary refractory patients was saved with pulse steroid + cyclosporine + vincristine. Now, he is disease free for over one year. The other refractory patient did not develop any response to salvage therapy and expired on day 15 with status epilepticus and ventilator related pneumonia (mortality rate 1/11). A CR was obtained with adjuvant treatments in all three PR patients. Only one CR patient developed an early relapse (early relapse rate in CR patients 1/6). She was treated successfully with daily PE plus vincristine. Our median follow up period was 25 months (range 9-108). Considering our local population, our annual incidence is only about 0.63 new cases per one million people. This figure is considerably less than the data from US, which indicated an incidence of 3.7 cases per 1,000,000. To our knowledge, there is no high variability in the incidence of TTP in the different geographical regions of the world. It suggests that considerable number of patients escaped notice. We hope that, demonstrating the successful outcome, this article serves to urge primary physicians to keep in mind the diagnosis of TTP and refer suspected cases quickly.
- Published
- 2007